Vikram Karnani: Q1 Revenue Reaches $193.52 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy COLL?
Reports Q1 revenue $193.52M, consensus $184.46M. "In the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continued durability from our pain portfolio" said Vikram Karnani, President and Chief Executive Officer. "We generated additional growth for JORNAY PM, with net revenue up 36% and prescriptions rising 14% driven by gains in both new prescribers and market share. We are encouraged by the impact of our expanded ADHD salesforce and marketing initiatives and look forward to integrating AZSTARYS following the expected close of the transaction. The pending acquisition of AZSTARYS represents an important next step in strengthening our ADHD portfolio, extending revenues into the late 2030s, and expanding our growth profile. At the same time, our pain portfolio delivered another solid quarter of durable revenues, driven by differentiated products and deliberate actions taken to enhance profitability. We remain focused on executing our strategy to build a leading diversified biopharmaceutical company while improving the lives of people living with serious medical conditions."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COLL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COLL
Wall Street analysts forecast COLL stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.330
Low
55.00
Averages
56.75
High
60.00
Current: 39.330
Low
55.00
Averages
56.75
High
60.00
About COLL
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Collegium Pharmaceutical Q1 2026 Earnings Call Highlights
- Strategic Acquisition Progress: Collegium Pharmaceutical plans to acquire AZSTARYS for $650 million, which is expected to enhance its position in the ADHD market and extend revenue through patent protection until 2037, thereby accelerating the company's growth trajectory.
- Strong Financial Performance: In Q1, JORNAY prescriptions grew by 14% year-over-year, generating $38.9 million in net revenue, a 36% increase, while total product revenues reached $193.5 million, indicating stable performance in core products.
- Cash Flow and Liquidity: Collegium generated over $57.1 million in cash from operations in Q1, ending the quarter with over $421.8 million in cash, up $35 million from the end of 2025, enhancing the company's financial flexibility.
- Optimistic Market Outlook: Management reaffirmed its 2026 financial guidance, projecting total product revenues between $805 million and $825 million, with JORNAY revenue expected to be between $190 million and $200 million, reflecting confidence in future growth.
See More
Collegium Pharmaceutical Q1 Earnings Exceed Expectations
- Earnings Beat: Collegium Pharmaceutical reported Q1 2026 non-GAAP EPS of $1.76, surpassing expectations by $0.24, indicating strong profitability growth that boosts investor confidence.
- Revenue Growth: The company achieved total revenue of $193.5 million in Q1, an 8.8% year-over-year increase, exceeding market expectations by $9.04 million, reflecting sustained competitiveness in the market, particularly in pain management.
- Product Line Performance: The pain portfolio generated net revenues of $154.6 million, up 4% year-over-year, with Belbuca® and Xtampza®ER net revenues of $52.6 million and $50.8 million, respectively, growing 2% and 7%, demonstrating stable market demand and acceptance.
- Financial Guidance: Collegium projects 2026 product net revenues between $805 million and $825 million, with adjusted EBITDA expected to be between $455 million and $475 million, reflecting confidence in future growth, especially following the acquisition of Azstarys to expand its ADHD portfolio.
See More
Collegium Pharmaceutical Reports Strong Q1 Earnings Growth
- Significant Earnings Growth: Collegium Pharmaceutical reported a net income of $14.49 million for Q1, translating to $0.40 per share, a substantial increase from last year's $2.42 million and $0.07 per share, indicating a marked improvement in profitability.
- Strong Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $69.21 million, or $1.76 per share, reflecting sustained growth and enhanced profitability in its core operations.
- Steady Revenue Increase: Q1 revenue rose by 8.9% to $193.52 million, up from $177.75 million last year, showcasing the company's success in meeting market demand and effective sales strategies.
- Optimistic Future Outlook: Collegium anticipates full-year revenue guidance of $805 million to $825 million for 2026, along with expected adjusted EBITDA of $455 million to $475 million, demonstrating confidence in future growth and strategic planning.
See More
Collegium Pharmaceutical to Announce Q1 Earnings on May 7
- Earnings Announcement: Collegium Pharmaceutical is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimates at $1.52, reflecting a 2.0% year-over-year increase, and revenue expectations at $184.46 million, up 3.7%, providing critical performance insights for investors.
- Performance Beat Record: Over the past two years, Collegium has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a strong track record of profitability and market performance, which may bolster investor confidence.
- Estimate Revision Trends: Despite no upward revisions in EPS estimates over the last three months, there have been four downward adjustments, and similarly, revenue estimates saw three downward revisions, reflecting a cautious market outlook on the company's future performance that investors should monitor closely.
- Acquisition Strategy: Collegium plans to acquire the ADHD medication Azstarys for up to $785 million, targeting a 31% revenue growth for Jornay by 2026, which not only expands its ADHD portfolio but also accelerates overall company growth, enhancing its competitive position in the market.
See More
Collegium Pharmaceutical Executive Sells Shares
- Insider Trading: David Dieter, Executive VP and General Counsel of Collegium Pharmaceutical, sold 6,224 shares on March 9, 2026, for $228,110, marking his first open-market transaction since joining the company.
- Stake Reduction: This sale reduced Dieter's direct holdings from 97,271 to 91,047 shares, impacting 6.4% of his equity stake, yet he retains approximately $3.39 million in shares, indicating ongoing confidence in the company.
- Planned Transaction: The sale was executed under a pre-scheduled 10b5-1 trading plan adopted on December 5, 2025, suggesting a cautious approach rather than a discretionary move, reflecting the executive's strategic market engagement.
- Business Transition: Collegium is undergoing a significant business transition with 2025 revenue of $631.7 million, a 6% increase, and projected 2026 revenue of $805-$825 million, highlighting growth potential in the ADHD treatment sector.
See More
Collegium Pharmaceutical Executive Sells Shares
- Executive Share Sale: Dieter David, Executive Vice President and General Counsel of Collegium Pharmaceutical, sold 6,224 shares of common stock on March 9, 2026, for approximately $228,000, representing 6.4% of his direct holdings prior to the transaction.
- Updated Holdings: Post-transaction, David retains 91,047 shares valued at about $3.39 million, indicating his ongoing confidence in the company’s future, although the sale was executed under a pre-scheduled plan.
- Financial Performance: Collegium reported total revenue of $631.7 million in 2025, a 6% year-over-year increase, with Jornay PM showing a remarkable 48% growth, and is projected to generate $190-$200 million in 2026, highlighting strong growth potential in the ADHD treatment sector.
- Strategic Transition Signal: The share sale occurred just ten days before Collegium announced its acquisition of AZSTARYS for $650 million, signaling an acceleration in the company's shift from a focus solely on pain management products to a more diversified portfolio in mental health treatments.
See More
Collegium Pharmaceutical Q1 2026 Earnings Call Highlights
- Strategic Acquisition Progress: Collegium Pharmaceutical plans to acquire AZSTARYS for $650 million, which is expected to enhance its position in the ADHD market and extend revenue through patent protection until 2037, thereby accelerating the company's growth trajectory.
- Strong Financial Performance: In Q1, JORNAY prescriptions grew by 14% year-over-year, generating $38.9 million in net revenue, a 36% increase, while total product revenues reached $193.5 million, indicating stable performance in core products.
- Cash Flow and Liquidity: Collegium generated over $57.1 million in cash from operations in Q1, ending the quarter with over $421.8 million in cash, up $35 million from the end of 2025, enhancing the company's financial flexibility.
- Optimistic Market Outlook: Management reaffirmed its 2026 financial guidance, projecting total product revenues between $805 million and $825 million, with JORNAY revenue expected to be between $190 million and $200 million, reflecting confidence in future growth.
See More
Collegium Pharmaceutical Q1 Earnings Exceed Expectations
- Earnings Beat: Collegium Pharmaceutical reported Q1 2026 non-GAAP EPS of $1.76, surpassing expectations by $0.24, indicating strong profitability growth that boosts investor confidence.
- Revenue Growth: The company achieved total revenue of $193.5 million in Q1, an 8.8% year-over-year increase, exceeding market expectations by $9.04 million, reflecting sustained competitiveness in the market, particularly in pain management.
- Product Line Performance: The pain portfolio generated net revenues of $154.6 million, up 4% year-over-year, with Belbuca® and Xtampza®ER net revenues of $52.6 million and $50.8 million, respectively, growing 2% and 7%, demonstrating stable market demand and acceptance.
- Financial Guidance: Collegium projects 2026 product net revenues between $805 million and $825 million, with adjusted EBITDA expected to be between $455 million and $475 million, reflecting confidence in future growth, especially following the acquisition of Azstarys to expand its ADHD portfolio.
See More
Collegium Pharmaceutical Reports Strong Q1 Earnings Growth
- Significant Earnings Growth: Collegium Pharmaceutical reported a net income of $14.49 million for Q1, translating to $0.40 per share, a substantial increase from last year's $2.42 million and $0.07 per share, indicating a marked improvement in profitability.
- Strong Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $69.21 million, or $1.76 per share, reflecting sustained growth and enhanced profitability in its core operations.
- Steady Revenue Increase: Q1 revenue rose by 8.9% to $193.52 million, up from $177.75 million last year, showcasing the company's success in meeting market demand and effective sales strategies.
- Optimistic Future Outlook: Collegium anticipates full-year revenue guidance of $805 million to $825 million for 2026, along with expected adjusted EBITDA of $455 million to $475 million, demonstrating confidence in future growth and strategic planning.
See More
Collegium Pharmaceutical to Announce Q1 Earnings on May 7
- Earnings Announcement: Collegium Pharmaceutical is set to release its Q1 2023 earnings on May 7 before market open, with consensus EPS estimates at $1.52, reflecting a 2.0% year-over-year increase, and revenue expectations at $184.46 million, up 3.7%, providing critical performance insights for investors.
- Performance Beat Record: Over the past two years, Collegium has exceeded EPS estimates 63% of the time and revenue estimates 75% of the time, indicating a strong track record of profitability and market performance, which may bolster investor confidence.
- Estimate Revision Trends: Despite no upward revisions in EPS estimates over the last three months, there have been four downward adjustments, and similarly, revenue estimates saw three downward revisions, reflecting a cautious market outlook on the company's future performance that investors should monitor closely.
- Acquisition Strategy: Collegium plans to acquire the ADHD medication Azstarys for up to $785 million, targeting a 31% revenue growth for Jornay by 2026, which not only expands its ADHD portfolio but also accelerates overall company growth, enhancing its competitive position in the market.
See More
Collegium Pharmaceutical Executive Sells Shares
- Insider Trading: David Dieter, Executive VP and General Counsel of Collegium Pharmaceutical, sold 6,224 shares on March 9, 2026, for $228,110, marking his first open-market transaction since joining the company.
- Stake Reduction: This sale reduced Dieter's direct holdings from 97,271 to 91,047 shares, impacting 6.4% of his equity stake, yet he retains approximately $3.39 million in shares, indicating ongoing confidence in the company.
- Planned Transaction: The sale was executed under a pre-scheduled 10b5-1 trading plan adopted on December 5, 2025, suggesting a cautious approach rather than a discretionary move, reflecting the executive's strategic market engagement.
- Business Transition: Collegium is undergoing a significant business transition with 2025 revenue of $631.7 million, a 6% increase, and projected 2026 revenue of $805-$825 million, highlighting growth potential in the ADHD treatment sector.
See More
Collegium Pharmaceutical Executive Sells Shares
- Executive Share Sale: Dieter David, Executive Vice President and General Counsel of Collegium Pharmaceutical, sold 6,224 shares of common stock on March 9, 2026, for approximately $228,000, representing 6.4% of his direct holdings prior to the transaction.
- Updated Holdings: Post-transaction, David retains 91,047 shares valued at about $3.39 million, indicating his ongoing confidence in the company’s future, although the sale was executed under a pre-scheduled plan.
- Financial Performance: Collegium reported total revenue of $631.7 million in 2025, a 6% year-over-year increase, with Jornay PM showing a remarkable 48% growth, and is projected to generate $190-$200 million in 2026, highlighting strong growth potential in the ADHD treatment sector.
- Strategic Transition Signal: The share sale occurred just ten days before Collegium announced its acquisition of AZSTARYS for $650 million, signaling an acceleration in the company's shift from a focus solely on pain management products to a more diversified portfolio in mental health treatments.
See More
